Examkin

Question

Difficulty: MediumMedical History Evaluation

An adult male in his early sixties presents to an urgent care clinic with a three-day history of severe, diffuse muscle pain, profound generalized weakness, and passing tea-colored urine. His established medical background includes ischemic heart disease, hypercholesterolemia, and a recently identified supraventricular arrhythmia. His longstanding daily medication regimen consists of simvastatin, low-dose aspirin, and previously, metoprolol. His baseline laboratory records show mild, asymptomatic elevations in serum transaminases, and he is up to date on all age-appropriate cancer screenings. Eighteen days prior to this visit, a consulting specialist transitioned him from metoprolol to diltiazem for optimized chronotropic control. During the clinical interview, the patient also reports initiating a light treadmill walking routine last week. Physical examination reveals marked, diffuse tenderness across major muscle groups of the proximal extremities. During the targeted medical history evaluation for this patient's acute presentation, identifying which of the following details is most crucial for establishing the immediate etiology of his symptoms?

  1. The addition of a medication known to inhibit the cytochrome P450 3A4 isoenzymeAnswer
  2. B
    The onset of myalgias following the initiation of a novel aerobic exercise regimen
  3. C
    The patient's ongoing adherence to a longstanding daily lipophilic statin prescription
  4. D
    The patient's historical baseline of mild, asymptomatic transaminase elevations
  5. E
    The status of the patient's age-appropriate malignancy screening history

Answer

The addition of a medication known to inhibit the cytochrome P450 3A4 isoenzyme
The patient is presenting with classic signs of acute rhabdomyolysis, evidenced by severe diffuse muscle pain, weakness, and tea-colored urine (myoglobinuria). When evaluating this patient's medical history, the most critical finding is the recent addition of diltiazem to a regimen that already includes simvastatin. Simvastatin is extensively metabolized by the cytochrome P450 3A4 (CYP3A4) isoenzyme in the liver. Diltiazem (a non-dihydropyridine calcium channel blocker) is a well-known moderate inhibitor of CYP3A4. The concurrent use of these medications profoundly decreases the hepatic clearance of simvastatin, causing serum levels to rise to toxic thresholds and precipitating severe myopathy and rhabdomyolysis. Promptly identifying this historical detail dictates both the correct diagnosis and the immediate cessation of the offending agents.

Step-by-Step Solution

1
Analyze the patient's clinical presentation.
The combination of severe myalgias, profound weakness, and tea-colored urine strongly indicates acute rhabdomyolysis.
Recognizing the syndrome dictates the need to immediately identify the precipitating toxicologic or physical trigger.
2
Evaluate the timeline of the patient's medical and medication history.
The patient has been on stable doses of simvastatin, but diltiazem was added 18 days ago, shortly before the onset of symptoms.
Identifying recent changes in the patient's exposure history is crucial for uncovering iatrogenic causes of acute decompensation.
3
Assess for pharmacokinetic interactions among the active medications.
Diltiazem inhibits the CYP3A4 enzyme, which is required to metabolize simvastatin, leading to a sudden, toxic accumulation of the statin.
Understanding drug-drug interactions is a fundamental component of evaluating a patient's medication history to establish a definitive diagnosis.

Key Concept

Pharmacokinetic drug-drug interactions (specifically CYP3A4 inhibition by diltiazem) as a precipitant for statin-induced rhabdomyolysis, identified through meticulous medication history evaluation.
Rate this question

Topics

Medical History Evaluation

More questions from this topic